Donald Richieri Griffin

Donald Richieri Griffin

Auto-generated profile, based on publicly available information

Donald Richieri Griffin

Department of Biomedical Engineering, University of Virginia, Charlottesville, VA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
LPLauren Pruett
Lauren Pruett
CJChristian H. Jenkins
Christian H. Jenkins
NSNeharika S. Singh
Neharika S. Singh
KCKatarina J. Catallo
Katarina J. Catallo
DGDonald R. Griffin
Donald R. Griffin

6 January 2021 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
BPBlaise N. Pfaff
Blaise N. Pfaff
LPLauren J. Pruett
Lauren J. Pruett
NCNicholas J. Cornell
Nicholas J. Cornell
JRJoseph de Rutte
Joseph de Rutte
DCDino Di Carlo
Dino Di Carlo
DGDonald R. Griffin
Donald R. Griffin

17 May 2021 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
LPLauren Pruett
Lauren Pruett
RERegan Ellis
Regan Ellis
MMMeghan McDermott
Meghan McDermott
CRColleen Roosa
Colleen Roosa
DGDonald Griffin
Donald Griffin
Microporous annealed particle (MAP) hydrogel has been a promising scaffold platform technology to promote immediate tissue integration in injured tissue environments. The addition of growth factors has the potential to accelerate tissue integration and enhance scaffold-mediated healing. Growth factor releasing scaffolds face the translational hurdle of limited solubilized protein shelf stability; however, to address this hurdle we present a lyophilized MAP scaffold which can be effectively rehydrated directly prior to use. Our new approach includes a heterogenous MAP scaffold wherein 5% of the microgels contain immobilized heparin loaded with epidermal growth factor (EGF) at 1 μg mL−1. We demonstrate that these scaffolds, which are directly loaded with EGF following lyophilization maintain equivalent properties to scaffolds loaded passively via diffusion into water-swollen microgels, including EGF release profiles and cell migration studies that did not significantly differ. Further, these heterogeneous scaffolds exhibit a significant increase in cellular migration in vitro and quicker re-epithelialization in vivo. This progress on spatially heterogenous growth factor release from MAP scaffolds has great potential to improve complex wound treatment and advance the field of growth factor releasing scaffolds.

10 December 2019 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
LPLauren Pruett
Lauren Pruett
HKHeather Koehn
Heather Koehn
TMTeresa Martz
Teresa Martz
ICIan Churnin
Ian Churnin
SFSergio Ferrante
Sergio Ferrante
JDJames J. Daniero
James J. Daniero

23 February 2023 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
LPLauren Pruett
Lauren Pruett
HKHannah L. Kenny
Hannah L. Kenny
WSWilliam M. Swift
William M. Swift
KCKatarina J. Catallo
Katarina J. Catallo
ZAZoe R. Apsel
Zoe R. Apsel
JDJames J. Daniero
James J. Daniero
Biomaterial-enabled de novo formation of non-fibrotic tissue in situ would provide an important tool to physicians. One example application, glottic insufficiency, is a debilitating laryngeal disorder wherein vocal folds do not fully close, resulting in difficulty speaking and swallowing. Preferred management of glottic insufficiency includes bulking of vocal folds via injectable fillers, however, the current options have associated drawbacks including inflammation, accelerated resorption, and foreign body response. We developed a novel iteration of microporous annealed particle (MAP) scaffold designed to provide persistent augmentation. Following a 14-month study of vocal fold augmentation using a rabbit vocal paralysis model, most MAP scaffolds were replaced with tissue de novo that matched the mixture of fibrotic and non-fibrotic collagens of the contralateral vocal tissue. Further, persistent tissue augmentation in MAP-treated rabbits was observed via MRI and via superior vocal function at 14 months relative to the clinical standard.

13 November 2023 in Advanced Biology
Verified
Journal Article
Open access
BPBlaise N. Pfaff
Blaise N. Pfaff
CFClare C. Flanagan
Clare C. Flanagan
DGDonald R. Griffin
Donald R. Griffin
Scaffold pore architecture is shown to influence stem cell fate through various avenues. It is demonstrated that microporous annealed particle (MAP) microgel diameter can be tuned to control scaffold pore size and, in turn, modulate mesenchymal stem cell (MSC) survivability, proliferation, metabolism, and migration, thereby enhancing bioactivity and guiding future applications of MAP for regenerative medicine.